Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Supplement—December 2017
Global Health Security Supplement

Capacity Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance Monitoring in Africa Network

Eric S. HalseyComments to Author , Meera Venkatesan, Mateusz M. Plucinski, Eldin Talundzic, Naomi W. Lucchi, Zhiyong Zhou, Celine I. Mandara, Hawela Moonga, Busiku Hamainza, Abdoul Habib Beavogui, Simon Kariuki, Aaron M. Samuels, Laura C. Steinhardt, Don P. Mathanga, Julie Gutman, Yves Eric Denon, Aline Uwimana, Ashenafi Assefa, Jimee Hwang, Ya Ping Shi, Pedro Rafael Dimbu, Ousmane Koita, Deus S. Ishengoma, Daouda Ndiaye, and Venkatachalam Udhayakumar
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.S. Halsey, M.M. Plucinski, E. Talundzic, N.W. Lucchi, Z. Zhou, A.M. Samuels, L.C. Steinhardt, J. Gutman, J. Hwang, Y.P. Shi, V. Udhayakumar); US Agency for International Development, Washington, DC, USA (M. Venkatesan); National Institute for Medical Research, Tanga, Tanzania (C.I. Mandara, D.S. Ishengoma); National Malaria Control Centre, Lusaka, Zambia (H. Moonga, B. Hamainza); Mafèrinyah Rural Health Research Center, Mafèrinyah, Guinea (A.H. Beavogui); University Gamal Abdel Nasser of Conakry, Conakry, Guinea (A.H. Beavogui); Kenya Medical Research Institute, Kisumu, Kenya (S. Kariuki); US Centers for Disease Control and Prevention, Kisumu (A.M. Samuels); University of Malawi College of Medicine, Blantyre, Malawi (D.P. Mathanga); National Malaria Control Program, Cotonou, Benin (Y.E. Denon); Rwanda Biomedical Center, Kigali, Rwanda (A. Uwimana); Ethiopian Public Health Institute, Addis Ababa, Ethiopia (A. Assefa, P.R. Dimbu); National Malaria Control Program, Luanda, Angola (P.R. Dimbu); University of Bamako, Mali (O. Koita); Université Cheikh Anta Diop de Dakar, Senegal (D. Ndiaye)

Main Article


Antimalarial drug resistance genes that may be analyzed by the President’s Malaria Initiative–supported Antimalarial Resistance Monitoring in Africa Network*

Gene Chromosome Type of mutation Antimalarial drug(s) associated with resistance
Amodiaquine, chloroquine
Polymorphism Amodiaquine, chloroquine, lumefantrine, quinine
Change in copy number
Propeller domain of kelch
Artemisinin derivatives (e.g., artesunate)
plasmepsin 2 and 3 14 Change in copy number Piperaquine

*Markers are selected based on the needs and priorities of each country’s malaria control program. This list will be expanded as additional molecular markers are identified.

Main Article

Page created: November 20, 2017
Page updated: November 20, 2017
Page reviewed: November 20, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.